Literature DB >> 20192278

The safety and tolerability of newer antiepileptic drugs in children and adolescents.

Dean P Sarco1, Blaise F D Bourgeois.   

Abstract

The newer antiepileptic drugs (AEDs) provide more therapeutic options and overall improved safety and tolerability for patients. To provide the best care, physicians must be familiar with the latest tolerability and safety data. This is particularly true in children, given there are relatively fewer studies examining the effects of AEDs in children compared with adults. Since we now have significant paediatric literature on each of these agents, we provide a comprehensive and current literature review of the newer AEDs, focusing on safety and tolerability data in children and adolescents. Because the safety profiles in children differ from those in adults, familiarity with this literature is important for child neurologists and other paediatric caregivers. We have organized the data by organ system for each AED for easier reference.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20192278     DOI: 10.2165/11310980-000000000-00000

Source DB:  PubMed          Journal:  CNS Drugs        ISSN: 1172-7047            Impact factor:   5.749


  384 in total

1.  [Lamotrigine-induced agranulocytosis].

Authors:  M Fernández-Galán; G Martín-Núñez; F Castellanos; M López-López
Journal:  Med Clin (Barc)       Date:  2000-12-02       Impact factor: 1.725

2.  Sensorineural hearing loss: a reversible effect of vigabatrin.

Authors:  E Papadeas; P Polychronopoulos; P Papathanasopoulos; C Frimas; N Pharmakakis; C Paschalis
Journal:  Neurology       Date:  2003-10-14       Impact factor: 9.910

Review 3.  Levetiracetam in pediatrics.

Authors:  Federico Vigevano
Journal:  J Child Neurol       Date:  2005-02       Impact factor: 1.987

4.  Psychiatric adverse events during vigabatrin therapy.

Authors:  D F Levinson; O Devinsky
Journal:  Neurology       Date:  1999-10-22       Impact factor: 9.910

5.  Felbamate in refractory partial epilepsy.

Authors:  R Canger; A Vignoli; R Bonardi; L Guidolin
Journal:  Epilepsy Res       Date:  1999-03       Impact factor: 3.045

6.  Randomized trial of vigabatrin in patients with infantile spasms.

Authors:  R D Elterman; W D Shields; K A Mansfield; J Nakagawa
Journal:  Neurology       Date:  2001-10-23       Impact factor: 9.910

7.  Felbamate in therapy-resistant epilepsy: an Italian experience. Felbamate Italian Study Group.

Authors:  G Avanzini; R Canger; B Dalla Bernardina; F Vigevano
Journal:  Epilepsy Res       Date:  1996-11       Impact factor: 3.045

8.  Drug induced encephalopathy in six epileptic patients: topiramate? valproate? or both?

Authors:  Patrick Latour; Arnaud Biraben; Elisabeth Polard; Danièle Bentué-Ferrer; Anne Beauplet; Olivier Tribut; Hervé Allain
Journal:  Hum Psychopharmacol       Date:  2004-04       Impact factor: 1.672

9.  Thyroid function in girls with epilepsy with carbamazepine, oxcarbazepine, or valproate monotherapy and after withdrawal of medication.

Authors:  Leena K Vainionpää; Kirsi Mikkonen; Johanna Rättyä; Mikael Knip; Arto J Pakarinen; Vilho V Myllylä; Jouko I T Isojärvi
Journal:  Epilepsia       Date:  2004-03       Impact factor: 5.864

10.  Topiramate monotherapy in infantile spasm.

Authors:  Young-Se Kwon; Yong-Hoon Jun; Young-Jin Hong; Byong-Kwan Son
Journal:  Yonsei Med J       Date:  2006-08-31       Impact factor: 2.759

View more
  2 in total

1.  Adjunctive Eslicarbazepine Acetate in Pediatric Patients with Focal Epilepsy: A Systematic Review and Meta-Analysis.

Authors:  Simona Lattanzi; Francesco Brigo; Elisabetta Grillo; Claudia Cagnetti; Alberto Verrotti; Gaetano Zaccara; Mauro Silvestrini
Journal:  CNS Drugs       Date:  2018-03       Impact factor: 5.749

2.  Design, synthesis, and pharmacological evaluation of [1, 3] dioxolo-chromeno[2,3-b]pyridines as anti-seizure agents.

Authors:  Visarapu Malathi; Nissi Sharon; Pannala Padmaja; Deepak Lokwani; Saurabh Khadse; Prashant Chaudhari; Atul A Shirkhedkar; Pedavenkatagari Narayana Reddy; Vinod G Ugale
Journal:  Mol Divers       Date:  2022-10-10       Impact factor: 3.364

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.